Biblio

Journal Article
Leclerc M, Fourati S, Menouche D, Challine D, Maury S. Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors. Lancet Haematol. 2021.
Tamari R, Castro-Malaspina H. Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms. Curr Opin Hematol. 2015.
Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, et al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantatio. Br J Haematol. 2019.
Li VWK, Yim R, Lee P, Chin L, Au L, Leung GMK, Sim J, Lie AKW, Tse E, Kwong Y-L, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction. Ann Hematol. 2023.
Kondo S, Inoue T, Saito T, Kawamura Y, Katayama A, Nakamura M, Sumitani R, Takahashi M, Oura M, Sogabe K, et al. Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength. BMJ Support Palliat Care. 2022.
Holtick U, Chemnitz JM, Hallek M, Scheid C. [Allogeneic Haematopoietic Stem Cell Transplantation - An Overview]. Klin Monbl Augenheilkd. 2015;232(5):641-646.
Lindgaard SChristy. Allogeneic Haematopoietic Stem Cell Recipients Admitted to the Intensive Care Unit: Survival and Prognosis. Acta Haematol. 2016;135(4):226-227.
Sommer C, Cheng H-Y, Nguyen D, Dettling D, Yeung YAndy, Sutton J, Hamze M, Valton J, Smith J, Djuretic I, et al. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. Mol Ther. 2020.
Nikolic M, Stift A, Reinisch W, Vogelsang H, Matic A, Müller C, Torney Mvon Straus, Riss S. Allogeneic expanded-adipose derived stem cells in the treatment of rectovaginal fistulas in Crohn's disease. Colorectal Dis. 2020.
Del Bufalo F, Becilli M, Rosignoli C, De Angelis B, Algeri M, Hanssens L, Gunetti M, Iacovelli S, Pira GLi, Girolami E, et al. Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed/refractory BCP-ALL. Blood. 2023.
Yang Y, Bi X, Gergis M, Yi D, Hsu J, Gergis U. Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):112-116.
Fiz F, Marini C, Campi C, Massone AMaria, Podestà M, Bottoni G, Piva R, Bongioanni F, Bacigalupo A, Piana M, et al. Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood. 2015.
Razak A, Lei D, McDonald CA, Hunt RW, Miller SL, Malhotra A. Allogeneic Cell Therapy Applications in Neonates: A Systematic Review. Stem Cells Transl Med. 2023.
Rieger AC, Tompkins BA, Natsumeda M, Florea V, Banerjee MN, Rodriguez J, Rosado M, Porras V, Valasaki K, Takeuchi LM, et al. Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction. Stem Cells Transl Med. 2022;11(1):59-72.
Lipsitt A, Beattie L, Harstead E, Li Y, Goorha S, Maron G, Gottschalk S, Triplett B, Naik S. Allogeneic CD34 selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection. Pediatr Blood Cancer. 2022:e30166.
Schiess M, Suescun J, Doursout M-F, Adams C, Green C, Saltarrelli JG, Savitz S, Ellmore TM. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease. Mov Disord. 2021.
Shimosato Y, Tanoshima R, Tujimoto S-I, Takeuchi M, Shiba N, Kobayashi T, Ito S. Allogeneic bone marrow versus peripheral blood stem cell transplantation for hematological malignancies in children: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019.
Oltolini C, Piemontese S, Ripa M, Greco R, Nozza S, Corti C, Peccatori J, Scarpellini P, Ciceri F, Castagna A. Allogeneic bone marrow transplantation in HIV people with hematological malignancies: post-transplant cyclophosphamide to overcome the HLA-matching barrier. Transpl Infect Dis. 2020:e13551.
Çam SBurak, Ciftci E, Gürbüz N, Altun B, Korkusuz P. Allogeneic bone marrow mesenchymal stem cell-derived exosomes alleviate human hypoxic AKI-on-a-Chip within a tight treatment window. Stem Cell Res Ther. 2024;15(1):105.
Sterling CH, Tsai H-L, Holdhoff M, Bolaños-Meade J, Luznik L, Fuchs EJ, Huff CAnn, Gocke CB, Ali SAbbas, Borrello IM, et al. "Allogeneic blood or marrow transplant with non-myeloablative conditioning and high dose cyclophosphamide-based graft-versus-host disease prophylaxis for secondary central nervous system lymphoma". Transplant Cell Ther. 2021.
Liu J, Qiu P, Qin J, Wu X, Wang X, Yang X, Li B, Zhang W, Ye K, Peng Z, et al. Allogeneic adipose-derived stem cells promote ischemic muscle repair by inducing M2 macrophage polarization via the HIF-1α/IL-10 pathway. Stem Cells. 2020.
Ranjbar A, Hassanzadeh H, Jahandoust F, Miri R, Bidkhori HReza, Monzavi SMostafa, Sanjar-Moussavi N, Matin MM, Shariati-Sarabi Z. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr Res Transl Med. 2021;70(2):103324.
Li Y, Shi G, Liang W, Shang H, Li H, Han Y, Zhao W, Bai L, Qin C. Allogeneic Adipose-Derived Mesenchymal Stem Cell Transplantation Alleviates Atherosclerotic Plaque by Inhibiting Ox-LDL Uptake, Inflammatory Reaction and Endothelial Damage in Rabbits. Cells. 2023;12(15).
Ryu B, Sekine H, Homma J, Kobayashi T, Kobayashi E, Kawamata T, Shimizu T. Allogeneic adipose-derived mesenchymal stem cell sheet that produces neurological improvement with angiogenesis and neurogenesis in a rat stroke model. J Neurosurg. 2019:1-14.
Saha A, Palchaudhuri R, Lanieri L, Hyzy S, Riddle MJ, Panthera J, Eide C, Tolar J, Panoskaltsis-Mortari A, Gorfinkel L, et al. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice. Blood. 2024.

Pages